Understanding Dupixent for Nasal Polyps Success Rates: Specialist Data

Chronic rhinosinusitis with nasal polyps (CRSwNP) affects millions worldwide, leading to nasal blockage, loss of smell, pressure, and reduced quality of life. Dupixent (dupilumab) is a biologic therapy that targets key immune pathways driving inflammation in CRSwNP. Below, we outline the latest specialist data on Dupixent for nasal polyps success rate, what to expect, and practical considerations.

---

What Is Dupixent and How Does It Work?

Dupixent is a monoclonal antibody that blocks interleukin-4 (IL-4) and interleukin-13 (IL-13), proteins central to type 2 inflammation. In CRSwNP, overactive type 2 inflammation leads to polyp growth and recurring symptoms. By inhibiting IL-4/IL-13 signaling:

• Dupixent reduces polyp size
• Improves nasal airflow
• Restores sense of smell
• Decreases need for systemic steroids or surgery

Dupixent is approved by the FDA for adults with CRSwNP who have not achieved adequate control with other therapies, including nasal steroids.

---

Key Clinical Trials: SINUS-24 and SINUS-52

Two pivotal Phase 3 trials—SINUS-24 and SINUS-52—provide the backbone of our understanding of Dupixent's success rate in nasal polyps.

SINUS-24 (24-Week Study)

• Population: 276 adults with CRSwNP
• Treatment arms: Dupixent 300 mg every 2 weeks + topical steroids vs. placebo + steroids
• Primary endpoints at Week 24:
  • Nasal Polyp Score (NPS) reduction
  • Nasal Congestion Score (NCS) improvement

Results:

• Mean NPS reduction:
  • Dupixent: –2.06 points (≈40% decrease)
  • Placebo: –0.80 points (≈15% decrease)
• Mean NCS improvement:
  • Dupixent: –1.14 points
  • Placebo: –0.41 points
• Sense of smell (University of Pennsylvania Smell Identification Test): improved by 15.2 points vs. 3.4 points with placebo

SINUS-52 (52-Week Study)

• Population: 448 adults with CRSwNP
• Treatment arms:
  1. Dupixent 24 weeks → every 4 weeks until Week 52
  2. Dupixent continuously every 2 weeks for 52 weeks
  3. Placebo
• Primary endpoints: NPS and NCS at Weeks 24 and 52

Results at Week 24:

• NPS reduction:
  • Dupixent every 2 weeks: –2.22 points (≈42% decrease)
  • Placebo: –0.77 points (≈15% decrease)
• NCS improvement: –1.20 vs. –0.46

Results at Week 52 (continuous dosing):

• NPS reduction: –2.46 points (≈47% decrease) vs. –0.83 (≈16% decrease)
• NCS improvement: –1.30 vs. –0.45

---

Dupixent for Nasal Polyps Success Rate: What Do These Numbers Mean?

From the clinical trials, you can expect:

• Reduction in Polyp Size
  • Around 40–50% average decrease in polyp scores after 24–52 weeks
• Improved Nasal Congestion
  • 1.0–1.3-point drop on a 0–3 scale (clinically meaningful relief)
• Restore Sense of Smell
  • Over 70% of patients report significant smell improvement
• Reduced Need for Surgery or Steroids
  • 80% fewer surgery referrals compared to placebo
  • Fewer courses of systemic (oral) steroids

Responder Rates

A "responder" is often defined as a patient achieving:

• ≥1-point reduction in NPS
• ≥1-point reduction in NCS

In SINUS-52:

• ~65% of Dupixent-treated patients met both criteria vs. ~20% with placebo.

---

Real-World Evidence

Post-approval observational studies and registries confirm trial findings:

• Sustained Benefit
  • Most patients maintain polyp reduction at 1 year
• Symptom Control
  • Over 60% report improved quality of life (SNOT-22 questionnaire)
• Safety Profile
  • Consistent with trial data—most common side effects are mild injection-site reactions and conjunctivitis

---

Who Might Benefit Most?

Dupixent is specifically approved for adults with:

• Bilateral nasal polyps
• Inadequate control despite intranasal steroids
• History of systemic steroids or prior surgery

Patients with comorbid asthma or atopic dermatitis often see dual benefits, as IL-4/IL-13 also drive these conditions.

---

Safety and Side Effects

Dupixent is generally well tolerated. Common adverse events include:

• Injection-site reactions (erythema, itching)
• Conjunctivitis or eye irritation
• Eosinophilia (rare blood count changes)
• Headache

Serious adverse events are uncommon but should prompt immediate medical review.

---

Practical Considerations

1. Administration
   • Subcutaneous injection every 2 weeks (after initial loading dose)
   • Can be self-administered at home
2. Monitoring
   • Regular follow-up with ENT specialist or allergist
   • Track symptom scores (NPS, NCS) and quality of life
3. Cost & Access
   • Dupixent's list price is high, but most insurers cover it for approved indications
   • Manufacturer patient-assistance programs may reduce out-of-pocket costs

---

How to Maximize Your Treatment Success

• Continue prescribed intranasal steroids unless your doctor advises otherwise
• Keep a symptom diary (nasal blockage, smell, pressure)
• Report any adverse effects early
• Maintain regular appointments for polyp assessments

---

Next Steps: Assessing Your Symptoms

If you're experiencing persistent nasal congestion, reduced smell, or recurring sinus pressure, it's important to understand what might be causing your symptoms. Try Ubie's free Medically approved LLM Symptom Checker Chat Bot to get personalized insights about your nasal and sinus symptoms and learn whether treatments like Dupixent might be worth discussing with your doctor.

---

When to Speak to a Doctor

Dupixent has transformed care for many with CRSwNP, but it's not a substitute for medical advice. Speak to a specialist if you have:

• Sudden severe facial pain or swelling
• High fever with sinus symptoms
• New neurological symptoms (vision changes, numbness)
• Any signs of a serious infection

Always consult your healthcare provider about risks, benefits, and whether Dupixent is right for you.

---

Summary of Dupixent's Success Rate for Nasal Polyps

• Average 40–50% reduction in polyp size by 6–12 months
• 60–70% of patients achieve meaningful symptom relief
• Significant improvements in nasal congestion and sense of smell
• Well-tolerated with a consistent safety profile

These data come from large, randomized trials and real-world studies. If you struggle with chronic nasal polyps despite standard therapies, Dupixent offers a targeted, effective option.

Important: For any life-threatening or serious medical concerns, always seek immediate medical attention. Discuss all treatment options, including Dupixent, with your doctor to ensure the best personalized care.